# Arcutis Biotherapeutics, Inc. (ARQT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Arcutis Biotherapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ARQT/mda/fy2025/): filed 2026-02-25; accession 0001787306-26-000018 (https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ARQT/mda/fy2024/): filed 2025-02-25; accession 0001787306-25-000029 (https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm)
- [FY 2023 MD&A](/company/ARQT/mda/fy2023/): filed 2024-02-27; accession 0001787306-24-000031 (https://www.sec.gov/Archives/edgar/data/1787306/000178730624000031/arqt-20231231.htm)
- [FY 2022 MD&A](/company/ARQT/mda/fy2022/): filed 2023-02-28; accession 0001787306-23-000023 (https://www.sec.gov/Archives/edgar/data/1787306/000178730623000023/arqt-20221231.htm)
- [FY 2021 MD&A](/company/ARQT/mda/fy2021/): filed 2022-02-22; accession 0001787306-22-000009 (https://www.sec.gov/Archives/edgar/data/1787306/000178730622000009/arqt-20211231.htm)

Back to /company/ARQT/